We are focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.

Our technology

The unique potential of Radiopharmaceuticals in treating oncological diseases.

Learn more

Our pipeline

The unique potential of being First to Market or Best in Class.

Learn more

Our team

We have a unique commitment to improve patients’ hope in fighting cancer.

Learn more

Information for investors

Stock price, Company governance & updates from our multiple development programs.

Learn more

Latest news

ASX Releases

NATURE publishes encouraging data on DUNP19 receptor role in cancer growth

October 4, 2022

Read moreRead more

ASX Releases

Ga68 - Integrin (RAD301) Selected for Presentation at EANM

September 27, 2022

Read moreRead more

ASX Releases

Pivalate Phase II Data to be Presented at October Conference in Barcelona

September 21, 2022

Read moreRead more